OneMedNet Reports Record Bookings with 50X Faster Fulfillment

MINNEAPOLIS, Sept. 18, 2026 /CourierPR/ -- OneMedNet Corporation, a leading provider of first-party regulatory decision-grade, AI-driven Real-World Data (RWD), has reported record bookings for the year-to-date period, with approximately $16.2 million in contracts, marking a 16X increase from the same period in 2025. According to the company, a significant portion of these bookings are expected to be delivered during the remainder of the year.

Aaron Green, CEO and President of OneMedNet, stated, "Our commercial engine is delivering. Bookings are up more than 16X year over year, and we are executing to our contracted delivery schedules. Expanding demand combined with disciplined execution is what builds durable value."

Approximately 50% of the contracts booked during 2026 are with new customers, while the existing customer base continues to expand their business with the company through high rates of reorder and follow-on engagement. This growth reflects the company's network of more than 2,300 healthcare partner sites and more than 90 million patient journeys and 270 million studies, which form the backbone of its iRWD™ platform.

OneMedNet has also seen significant improvements in its order-fulfillment speed, with platform enhancements increasing the speed by approximately 50X. This acceleration allows the company to take on larger orders while providing quick delivery to meet its customers' project schedules.

The company's iRWD™ Platform is designed to support a wide range of applications, from drug development to AI-driven research, leveraging the power of real-world data to drive innovation. With a network spanning rare diseases, oncology, cardiology, and more, OneMedNet is well-positioned to deliver precision insights that support patient care and the next wave of healthcare innovation.

OneMedNet Corporation (Nasdaq: ONMD) is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the potential of its extensive network to support the needs of the life sciences, medical device, and AI industries. The company's iRWD™ platform is a cornerstone of its mission to provide regulatory decision-grade data, driving innovation and improving patient outcomes.

The company's forward-looking statements, including those regarding demand for its products and services, the composition and durability of its customer base, and the speed of order fulfillment, are subject to risks and uncertainties. These include the company's ability to keep pace with new technology and changing market needs, the competitive environment, and the timing of customer acceptance and data delivery.